Physician profile
David A Baird
NPI 1326124652
$3,119.39
in general payments reported to CMS, 2019-2025
14 companies · $392 in 2025
The $392 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $347 · 2021: $496 · 2022: $482 · 2023: $668 · 2024: $524 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,232 · Education: $352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,232.02 |
| Education | $351.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,958.66 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $332.04 | 2019-2025 | |
| Pfizer INC. | $264.44 | 2019-2024 | |
| Lilly USA, LLC | $185.76 | 2019-2021 | |
| Abbvie INC. | $150.43 | 2019-2025 | |
| Amgen INC. | $46.01 | 2021-2023 | Enbrel, Otezla |
| Dermavant Sciences, INC. | $40.90 | 2023-2024 | Vtama |
| Epi Health, LLC | $26.76 | 2019-2020 | |
| Organon LLC | $26.08 | 2025 | Vtama |
| Janssen Scientific Affairs, LLC | $21.98 | 2022 | |
| Sandoz INC. | $21.79 | 2023 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.15 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.79 | 2020 | |
| Galderma Laboratories, L.P. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.